Elevated survivin is associated with a poor response to chemotherapy and reduced survival in lung cancer with malignant pleural effusions
- 2 November 2011
- journal article
- Published by Springer Science and Business Media LLC in Clinical & Experimental Metastasis
- Vol. 29 (2), 83-89
- https://doi.org/10.1007/s10585-011-9431-7
Abstract
Survivin has been shown to inhibit apoptosis, enhance proliferation and promote angiogenesis. This study aimed to identify diagnostic value of survivin protein in malignant pleural effusion (MPE) and to investigate the prediction of response to chemotherapy and the prognostic role on pleural survivin in lung cancer patients with MPE. Pleural effusion samples were collected from 67 patients with MPE (58 lung cancers; 9 extrathoracic tumors), and from 68 patients with benign conditions (31 with pneumonia; 37 with tuberculosis). Concentrations of pleural fluid survivin, Cyfra 21-1, and carcinoembryonic antigen (CEA) were measured by enzyme-linked immunosorbent assay. The expression profile of survivin in pleural fluid, and its association with survival, were investigated. Survivin levels were significantly elevated in patients with MPE, especially primary lung cancer than in those of benign origin. Survivin, Cyfra 21-1, and CEA varied in diagnostic accuracy for differentiating MPE from benign pleural effusion by 67.5, 68.3, and 93.4%, respectively. Lung cancer patients with MPE who were positive for survivin expression were more refractory to chemotherapy (P = 0.003). Positive for survivin expression was correlated with a reduced overall survival in univariate (P = 0.0001) and multivariate (P = 0.004) analyses. Using the appropriate cut-off points, CEA in pleural fluid has a higher accuracy than other tumor markers, and that survivin has a low diagnostic accuracy for differentiating MPE from benign pleural effusion. Our findings suggest that positive survivin expression may be used as a predictor of a poor response to chemotherapy and shorter survival in lung cancer patients with MPE.Keywords
This publication has 28 references indexed in Scilit:
- Quantitative detection of survivin in malignant pleural effusion for the diagnosis and prognosis of lung cancerCancer Letters, 2009
- Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysisThorax, 2008
- Survivin: A promising tumor biomarkerCancer Letters, 2007
- Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21‐1 in patients with pleural effusion: a systematic review and meta‐analysisJournal of Clinical Laboratory Analysis, 2007
- IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genesAmerican Journal of Hematology, 2006
- Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B‐cell lymphoma and its subtypesPathology International, 2005
- Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancerAnnals Of Oncology, 2004
- Improving tumor cell detection in pleural effusions by interphase cytogeneticsCytometry Part B: Clinical Cytometry, 2003
- Survivin gene expression in early‐stage non‐small cell lung cancerThe Journal of Pathology, 2003
- Malignant effusions: Diagnostic evaluation and therapeutic strategyCurrent Problems in Cancer, 1981